Cargando…

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05

BACKGROUND: To investigate intravitreal treatment efficiencies in patients suffering from exudative ARMD with a BCVA ≤ 0.05. METHODS: Retrospective analysis: Analysis parameters were lesion type, BCVA at baseline and at follow-up, the intravitreal drug used, and its application frequency. Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Raphael, Schmidt, Matthias, Gebauer, Sabine, Busse, Holger, Uhlig, Constantin E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618933/ https://www.ncbi.nlm.nih.gov/pubmed/26490832 http://dx.doi.org/10.1186/s12886-015-0123-y

Ejemplares similares

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
por: Chang, Young Suk, et al.
Publicado: (2014)

Current Smoking Is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration
por: Lee, Sangmoon, et al.
Publicado: (2013)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi, Hidenori, et al.
Publicado: (2018)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Origin of colossal dielectric permittivity of rutile Ti(0.9)In(0.05)Nb(0.05)O(2): single crystal and polycrystalline
por: Song, Yongli, et al.
Publicado: (2016)

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone
por: Ruiz-Moreno, José Mª, et al.
Publicado: (2008)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study
por: Minturn, Robert J., et al.
Publicado: (2021)

Efficacy of 0.05% Chlorhexidine and 0.05% Cetylpyridinium Chloride Mouthwash to Eliminate Living Bacteria on In Situ Collected Biofilms: An In Vitro Study
por: Becker, Kathrin, et al.
Publicado: (2021)

Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!
por: Kwak, Sanggyu
Publicado: (2023)

0.05 - 100 MHz 4 W amplifier
por: Paoluzzi, M
Publicado: (1997)

Halometasone monohydrate (0.05%) in occupational contact dermatitis
por: Maiti, Rituparna, et al.
Publicado: (2016)

A Primary Dead-Weight Tester for Pressures (0.05–1.0) MPa
por: Jain, Kamlesh, et al.
Publicado: (2003)

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
por: Davis, R Prince, et al.
Publicado: (2010)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Shaikh, Saad, et al.
Publicado: (2007)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
por: Nakamura, Tomoko, et al.
Publicado: (2012)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Retinal pigment epithelial tear after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Singh, Sunil Kumar, et al.
Publicado: (2014)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration
por: Koss, Michael Janusz, et al.
Publicado: (2014)

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
por: Jeon, Sohee, et al.
Publicado: (2014)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

Electrochemical properties of La(0.5)Sr(0.5)Fe(0.95)Mo(0.05)O(3−δ) as cathode materials for IT-SOEC
por: Hou, Yunting, et al.
Publicado: (2021)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Foveal threshold and photoreceptor integrity for prediction of visual acuity after intravitreal aflibercept on age-related macular degeneration
por: Sakai, Tsutomu, et al.
Publicado: (2018)

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
por: Molinelli, Elisa, et al.
Publicado: (2020)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Electronic, electrical and thermoelectric properties of Ba(0.95)Ca(0.05)Ti(0.95)Y(0.05)O(2.975) compound: Experimental study and DFT-mBJ calculation
por: Saidi, A., et al.
Publicado: (2023)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis
por: Ono, Aoi, et al.
Publicado: (2018)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

On the challenges of drawing conclusions from p-values just below 0.05
por: Lakens, Daniël
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h440ct4ki7t2enfinfje6ci6da